Evidence map›Paper›PMID 26829922›Full record

ArticleMicrobial cell factories2016

Microbial glycolipoprotein-capped silver nanoparticles as emerging antibacterial agents against cholera.

Geeta Gahlawat, Sristy Shikha, Baldev Singh Chaddha, Saumya Ray Chaudhuri, Shanmugam Mayilraj, Anirban Roy Choudhury

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 137 citations in OpenAlex.

  1. Article
  2. Metal oxide nanoparticles: emerging stars in biomedical application.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Metallic nanoparticles: a promising novel therapeutic tool against antimicrobial resistance and spread of superbugs.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  7. Biogenic synthesis of silver nanoparticle byFrontiers in microbiology · 2024
    Article
  8. The potential biological activities ofFrontiers in microbiology · 2024
    Article
  9. Article
  10. Review
  11. Review
  12. Biogenic Synthesis of Silver Nanoparticles UsingBioengineering (Basel, Switzerland) · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Geeta GahlawatCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. geeta.gahlawat@gmail.com.
Sristy ShikhaCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. sristyshikha@imtech.res.in.
Baldev Singh ChaddhaCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. bsbt89@gmail.com.
Saumya Ray ChaudhuriCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. saumya@imtech.res.in.
Shanmugam MayilrajCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. mayil@imtech.res.in.
Anirban Roy ChoudhuryCSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, 160036, India. anirban@imtech.res.in.
Institute of Microbial Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the increased number of cholera outbreaks and emergence of multidrug resistance in Vibrio cholerae strains it has become necessary for the scientific community to devise and develop novel therapeutic approaches against cholera. Recent studies have indicated plausibility of therapeutic application of metal nano-materials. Among these, silver nanoparticles (AgNPs) have emerged as a potential antimicrobial agent to combat infectious diseases. At present nanoparticles are mostly produced using physical or chemical techniques which are toxic and hazardous. Thus exploitation of microbial systems could be a green eco-friendly approach for the synthesis of nanoparticles having similar or even better antimicrobial activity and biocompatibility. Hence, it would be worth to explore the possibility of utilization of microbial silver nanoparticles and their conjugates as potential novel therapeutic agent against infectious diseases like cholera.

resultsThe present study attempted utilization of Ochrobactrum rhizosphaerae for the production of AgNPs and focused on investigating their role as antimicrobial agents against cholera. Later the exopolymer, purified from the culture supernatant, was used for the synthesis of spherical shaped AgNPs of around 10 nm size. Further the exopolymer was characterized as glycolipoprotein (GLP). Antibacterial activity of the novel GLP-AgNPs conjugate was evaluated by minimum inhibitory concentration, XTT reduction assay, scanning electron microscopy (SEM) and growth curve analysis. SEM studies revealed that AgNPs treatment resulted in intracellular contents leakage and cell lysis.

conclusionThe potential of microbially synthesized nanoparticles, as novel therapeutic agents, is still relatively less explored. In fact, the present study first time demonstrated that a glycolipoprotein secreted by the O. rhizosphaerae strain can be exploited for production of AgNPs which can further be employed to treat infectious diseases. Although this type of polymer has been obtained earlier from marine fungi and bacteria, none of these reports have studied the role of this polymer in AgNPs synthesis and its application in cholera therapy. Interestingly, the microbial GLP-capped AgNPs exhibited antibacterial activity against V. cholerae comparable to ciprofloxacin. Thus the present study may open up new avenues for development of novel therapeutic agents for treatment of infectious diseases. Graphical abstract Development of novel therapeutic agents for treatment of cholera.

Indexed as

Anti-Bacterial AgentsAntioxidantsBiopolymersBiphenyl CompoundsCholeraDynamic Light ScatteringFree Radical ScavengersGlycoproteinsLipoproteinsMetal NanoparticlesMicrobial Sensitivity TestsPhylogenyPicratesRNA, Ribosomal, 16SSilverSpectrometry, X-Ray Emission1,1-diphenyl-2-picrylhydrazylAnti-Bacterial AgentsAntioxidantsBiopolymersBiphenyl CompoundsFree Radical ScavengersGlycoproteinsLipoproteinsPicratesRNA, Ribosomal, 16SSilver

Identifiers

PMID26829922
PMCPMC4736657
OpenAlexW2263062100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.